A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

May 22, 2024

Study Completion Date

May 22, 2024

Conditions
Advanced Malignant Tumors
Interventions
DRUG

LBL-007 Injection

LBL-007 Injection; dose A or dose B; Q3W

DRUG

Toripalimab Injection

Toripalimab Injection; dose C; Q3W

Trial Locations (14)

213000

Changzhou Cancer Hospital, Changzhou

233060

The first affiliated hospital of bengbu medical University, Bengbu

250012

Qilu Hospital of Shandong University, Jinan

272007

Affiliated Hospital of Jining Medical University, Jining

276000

Linyi Cancer Hospital, Linyi

300202

Tianjin Medical University Cancer Institute & Hospital, Tianjin

351100

The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China, Fuzhou

404000

Chongqing University Three gorges Hospital, Chongqing

410013

Hunan Cancer Hospital, Changsha

430022

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

430079

Hubei Cancer Hospital, Wuhan

450008

Henan Cancer Hospital, Zhengzhou

510060

Sun Yat-sen University Cancer Center, Guangzhou

537000

The First People's Hospital of Yu Lin, Yulin

All Listed Sponsors
lead

Nanjing Leads Biolabs Co.,Ltd

INDUSTRY

NCT05102006 - A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter